RU2008122296A - Морфогенные белки кости (вмр), рецепторы вмр и связывающие вмр белки и их применение для диагностики и лечения глаукомы - Google Patents
Морфогенные белки кости (вмр), рецепторы вмр и связывающие вмр белки и их применение для диагностики и лечения глаукомы Download PDFInfo
- Publication number
- RU2008122296A RU2008122296A RU2008122296/15A RU2008122296A RU2008122296A RU 2008122296 A RU2008122296 A RU 2008122296A RU 2008122296/15 A RU2008122296/15 A RU 2008122296/15A RU 2008122296 A RU2008122296 A RU 2008122296A RU 2008122296 A RU2008122296 A RU 2008122296A
- Authority
- RU
- Russia
- Prior art keywords
- seq
- bmp
- glaucoma
- sequence
- primers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
1. Способ диагностирования глаукомы в пробе, полученной из клетки или жидкости организма, детектированием измененной экспрессии гена, члена семейства морфогенных белков кости, включающий следующие стадии: ! g) получение пробы ткани или жидкости от пациента с подозрением на глаукому; ! h) выделение ДНК из указанной пробы; ! i) получение множества праймеров для ПЦР, при этом каждый из указанных праймеров включает последовательность, состоящую из 18-1547 смежных нуклеотидов из последовательностей SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47 или SEQ ID NO:53; ! j) амплификация областей выделенной ДНК с использованием указанных праймеров с получением продукта ПЦР; ! k) выделение продукта ПЦР; и ! l) идентификация различий между последовательностью амплифицированной выделенной ДНК и последовательностью праймера, ! при этом различие между амплифицированной последовательностью и праймером является диагностическим признаком глаукомы. ! 2. Способ по п.1, отличающийся тем, что указанная проба ткани или жидкости представляет собой клетки крови или буккальные клетки. ! 3. Способ по п.1, отличающийся тем, что праймеры включают последовательности, состоящие из 20-100 смежных нуклеотидов из последовательностей SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47 или SEQ ID NO:53. ! 4. Способ по п.1, отличающийся тем, что праймеры включают последовательности, состоящие из 20-50 смежных нуклеотидов из последовательности SEQ ID NO:3. ! 5. Способ по п.1, отличающийся тем, что продукт ПЦР выделяют с помощью SSCP, DGGE, ASO или RFLP.
Claims (5)
1. Способ диагностирования глаукомы в пробе, полученной из клетки или жидкости организма, детектированием измененной экспрессии гена, члена семейства морфогенных белков кости, включающий следующие стадии:
g) получение пробы ткани или жидкости от пациента с подозрением на глаукому;
h) выделение ДНК из указанной пробы;
i) получение множества праймеров для ПЦР, при этом каждый из указанных праймеров включает последовательность, состоящую из 18-1547 смежных нуклеотидов из последовательностей SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47 или SEQ ID NO:53;
j) амплификация областей выделенной ДНК с использованием указанных праймеров с получением продукта ПЦР;
k) выделение продукта ПЦР; и
l) идентификация различий между последовательностью амплифицированной выделенной ДНК и последовательностью праймера,
при этом различие между амплифицированной последовательностью и праймером является диагностическим признаком глаукомы.
2. Способ по п.1, отличающийся тем, что указанная проба ткани или жидкости представляет собой клетки крови или буккальные клетки.
3. Способ по п.1, отличающийся тем, что праймеры включают последовательности, состоящие из 20-100 смежных нуклеотидов из последовательностей SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47 или SEQ ID NO:53.
4. Способ по п.1, отличающийся тем, что праймеры включают последовательности, состоящие из 20-50 смежных нуклеотидов из последовательности SEQ ID NO:3.
5. Способ по п.1, отличающийся тем, что продукт ПЦР выделяют с помощью SSCP, DGGE, ASO или RFLP.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33485201P | 2001-10-31 | 2001-10-31 | |
| US60/334,852 | 2001-10-31 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004116308/15A Division RU2336902C2 (ru) | 2001-10-31 | 2002-10-31 | Морфогенные белки кости (вмр), рецепторы вмр и связывающие вмр белки и их применение для диагностики и лечения глаукомы |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012120343/15A Division RU2012120343A (ru) | 2001-10-31 | 2012-05-16 | Морфогенные белки кости (bmp), рецепторы вмр и связывающие вмр белки и их применение для диагностики и лечения глаукомы |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008122296A true RU2008122296A (ru) | 2009-12-10 |
Family
ID=23309139
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004116308/15A RU2336902C2 (ru) | 2001-10-31 | 2002-10-31 | Морфогенные белки кости (вмр), рецепторы вмр и связывающие вмр белки и их применение для диагностики и лечения глаукомы |
| RU2008122296/15A RU2008122296A (ru) | 2001-10-31 | 2008-06-03 | Морфогенные белки кости (вмр), рецепторы вмр и связывающие вмр белки и их применение для диагностики и лечения глаукомы |
| RU2012120343/15A RU2012120343A (ru) | 2001-10-31 | 2012-05-16 | Морфогенные белки кости (bmp), рецепторы вмр и связывающие вмр белки и их применение для диагностики и лечения глаукомы |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004116308/15A RU2336902C2 (ru) | 2001-10-31 | 2002-10-31 | Морфогенные белки кости (вмр), рецепторы вмр и связывающие вмр белки и их применение для диагностики и лечения глаукомы |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012120343/15A RU2012120343A (ru) | 2001-10-31 | 2012-05-16 | Морфогенные белки кости (bmp), рецепторы вмр и связывающие вмр белки и их применение для диагностики и лечения глаукомы |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US7405192B2 (ru) |
| EP (2) | EP1440159B1 (ru) |
| JP (2) | JP4255382B2 (ru) |
| KR (4) | KR101072867B1 (ru) |
| CN (2) | CN1685055A (ru) |
| AT (1) | ATE349554T1 (ru) |
| BR (1) | BR0213738A (ru) |
| CA (1) | CA2463143A1 (ru) |
| DE (1) | DE60217152T2 (ru) |
| ES (1) | ES2278079T3 (ru) |
| HK (1) | HK1069851A1 (ru) |
| MX (1) | MXPA04003697A (ru) |
| PL (2) | PL214839B1 (ru) |
| RU (3) | RU2336902C2 (ru) |
| WO (1) | WO2003055443A2 (ru) |
| ZA (1) | ZA200402662B (ru) |
Families Citing this family (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60217152T2 (de) | 2001-10-31 | 2007-10-31 | Alcon Inc. | Knochen-morphogene proteine (bmp), bmp-rezeptoren und bmp-bindungsproteine und ihre verwendung bei der diagnose und behandlung des glaukoms |
| US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
| JP4705469B2 (ja) | 2003-05-28 | 2011-06-22 | 武田薬品工業株式会社 | 抗ｂａｍｂｉ抗体、及びそれを含有する大腸癌及び肝臓癌の診断剤又は治療剤 |
| CA2475769C (en) * | 2003-08-28 | 2018-12-11 | Veridex, Llc | Colorectal cancer prognostics |
| KR101520209B1 (ko) | 2003-11-06 | 2015-05-13 | 시애틀 지네틱스, 인크. | 리간드에 접합될 수 있는 모노메틸발린 화합물 |
| US9045553B2 (en) | 2004-05-27 | 2015-06-02 | Acceleron Pharma, Inc. | Cerberus/Coco derivatives and uses thereof |
| KR20070026650A (ko) | 2004-05-27 | 2007-03-08 | 악셀레론 파마 인코포레이티드 | 케르베루스/코코 유도체 및 그의 용도 |
| KR20120064120A (ko) | 2004-06-01 | 2012-06-18 | 제넨테크, 인크. | 항체 약물 접합체 및 방법 |
| DK1791565T3 (en) | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| EP1817059A2 (en) | 2004-12-01 | 2007-08-15 | Genentech, Inc. | Conjugates of 1,8-bis-naphthalimides with an antibody |
| AU2006289667A1 (en) * | 2005-09-08 | 2007-03-15 | Apollo Life Sciences Limited | Noggin and chimeric molecules thereof |
| CA2659464A1 (en) * | 2006-08-24 | 2008-02-28 | Alcon Research, Ltd. | Rnai-mediated inhibition of gremlin for treatment of iop-related conditions |
| US10059756B2 (en) | 2006-11-02 | 2018-08-28 | Acceleron Pharma Inc. | Compositions comprising ALK1-ECD protein |
| US8642031B2 (en) | 2006-11-02 | 2014-02-04 | Acceleron Pharma, Inc. | Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof |
| EP3181580A1 (en) | 2006-11-02 | 2017-06-21 | Acceleron Pharma Inc. | Alk1 receptor and ligand antagonists and uses thereof |
| AU2007332819A1 (en) | 2006-12-08 | 2008-06-19 | Acceleron Pharma Inc. | Uses of cerberus, coco and derivatives thereof |
| WO2009134428A2 (en) | 2008-05-02 | 2009-11-05 | Acceleron Pharma, Inc. | Methods and compositions for modulating angiogenesis and pericyte composition |
| JP6067222B2 (ja) | 2008-07-15 | 2017-01-25 | ジェネンテック， インコーポレイテッド | アントラサイクリン誘導体コンジュゲート、その調製方法及び抗腫瘍化合物としてのその用途 |
| AU2010292172A1 (en) | 2009-09-09 | 2012-05-03 | Centrose, Llc | Extracellular targeted drug conjugates |
| BR112012008848A2 (pt) | 2009-10-16 | 2019-09-24 | Scripps Research Inst | composição, e, método in vitro ou ex vivo para induzir células de mamífero não-pluripotente em células tronco pluripotentes induzidas |
| US20130089560A1 (en) * | 2010-03-17 | 2013-04-11 | Oncomed Pharmaceuticals Inc | Bone morphogenetic protein receptor binding agents and methods of their use |
| WO2011130598A1 (en) | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazepines and conjugates thereof |
| EP2579897A1 (en) | 2010-06-08 | 2013-04-17 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| EP2640727B1 (en) | 2010-11-17 | 2015-05-13 | Genentech, Inc. | Alaninyl maytansinol antibody conjugates |
| MX2013013054A (es) | 2011-05-12 | 2014-02-20 | Genentech Inc | Metodo de monitoreo de lc-ms/ms de reaccion multiple para detectar anticuerpos terapeuticos en muestras de animales utilizando peptidos de firma de estructura. |
| CN103987407B (zh) | 2011-10-14 | 2016-08-24 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓及其偶联物 |
| WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
| KR102119223B1 (ko) * | 2012-03-15 | 2020-06-05 | 서울대학교산학협력단 | 그렘린-1에 대한 항체 |
| PT2906253T (pt) | 2012-10-12 | 2018-11-05 | Medimmune Ltd | Conjugados de anticorpo anti-psma de pirrolobenzodiazepina |
| EA035405B1 (ru) | 2012-10-12 | 2020-06-08 | Медимьюн Лимитед | Пирролбензодиазепины и их конъюгаты |
| ES2660029T3 (es) | 2012-10-12 | 2018-03-20 | Medimmune Limited | Conjugados de anticuerpo-pirrolobenzodiazepinas |
| KR101995621B1 (ko) | 2012-10-12 | 2019-07-03 | 에이디씨 테라퓨틱스 에스에이 | 피롤로벤조디아제핀-항-cd22 항체 컨주게이트 |
| WO2014057114A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-anti-psma antibody conjugates |
| SI2906298T1 (sl) | 2012-10-12 | 2018-12-31 | Adc Therapeutics Sa | Konjugati pirolobenzodiazepin-protitelo |
| PT2906296T (pt) | 2012-10-12 | 2018-06-01 | Medimmune Ltd | Conjugados de pirrolobenzodiazepina-anticorpo |
| AU2013366493B2 (en) | 2012-12-21 | 2017-08-24 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| JP6527466B2 (ja) | 2012-12-21 | 2019-06-05 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | 増殖性疾患および自己免疫疾患の治療に使用するための非対称ピロロベンゾジアゼピンニ量体 |
| US9649390B2 (en) | 2013-03-13 | 2017-05-16 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| CA2901941C (en) | 2013-03-13 | 2020-04-07 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| WO2014140174A1 (en) | 2013-03-13 | 2014-09-18 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
| KR20150129718A (ko) | 2013-03-14 | 2015-11-20 | 리제너론 파아마슈티컬스, 인크. | Ｇｒｅｍ 1에 대한 인간 항체 |
| CN105636612B (zh) | 2013-08-12 | 2020-01-14 | 基因泰克公司 | 抗体-药物缀合物及使用和治疗方法 |
| US10010624B2 (en) | 2013-10-11 | 2018-07-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| EP3054986B1 (en) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| EP3054985B1 (en) | 2013-10-11 | 2018-12-26 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| WO2015095223A2 (en) | 2013-12-16 | 2015-06-25 | Genentech, Inc. | Peptidomimetic compounds and antibody-drug conjugates thereof |
| CR20160271A (es) | 2013-12-16 | 2016-12-02 | Genentech Inc | Compuestos peptidométicos y sus conjugados de anticuerpo-fármaco |
| EP3082876B1 (en) | 2013-12-16 | 2018-01-17 | Genentech, Inc. | 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
| EP3166624B1 (en) | 2014-07-09 | 2020-06-03 | Mayo Foundation for Medical Education and Research | Treating rotator cuff conditions |
| US10188746B2 (en) | 2014-09-10 | 2019-01-29 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| WO2016040825A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anthracycline disulfide intermediates, antibody-drug conjugates and methods |
| RU2017107502A (ru) | 2014-09-12 | 2018-10-12 | Дженентек, Инк. | Антитела и конъюгаты, сконструированные введением цистеина |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| PE20170905A1 (es) | 2014-09-17 | 2017-07-12 | Genentech Inc | Pirrolobenzodiazepinas y conjugados de anticuerpo-disulfuro de las mismas |
| MX2017006770A (es) | 2014-11-25 | 2018-02-09 | Adc Therapeutics Sa | Conjugados de pirrolobenzodiazepina y anticuerpo. |
| EP3226909A1 (en) | 2014-12-03 | 2017-10-11 | Genentech, Inc. | Quaternary amine compounds and antibody-drug conjugates thereof |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| WO2017011762A1 (en) | 2015-07-16 | 2017-01-19 | Mayo Foundation For Medical Education And Research | Treating rotator cuff conditions |
| MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
| KR101921784B1 (ko) * | 2015-10-13 | 2018-11-23 | 사회복지법인 삼성생명공익재단 | 그램린-1을 코딩하는 뉴클레오타이드 또는 그램린-1을 유효성분으로 포함하는 안 질환 예방 또는 치료용 약제학적 조성물 |
| MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
| MA45326A (fr) | 2015-10-20 | 2018-08-29 | Genentech Inc | Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation |
| GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
| GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| CN105807065B (zh) * | 2016-03-16 | 2018-10-02 | 沈慧勇 | BMP2和Noggin联合使用在制备强直性脊柱炎诊断试剂盒中的应用 |
| WO2017165734A1 (en) | 2016-03-25 | 2017-09-28 | Genentech, Inc. | Multiplexed total antibody and antibody-conjugated drug quantification assay |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| CN109152843A (zh) | 2016-05-20 | 2019-01-04 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
| JP7022080B2 (ja) | 2016-05-27 | 2022-02-17 | ジェネンテック， インコーポレイテッド | 部位特異的抗体－薬物複合体の特徴付けのための生化学分析的方法 |
| CN109476648B (zh) | 2016-06-06 | 2022-09-13 | 豪夫迈·罗氏有限公司 | 司维司群抗体-药物缀合物和使用方法 |
| WO2018031662A1 (en) | 2016-08-11 | 2018-02-15 | Genentech, Inc. | Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof |
| CN106086229B (zh) * | 2016-08-26 | 2019-08-16 | 广东省农业科学院动物科学研究所 | 鸡生长性状相关的分子标记及其鉴别方法和应用 |
| JP7050770B2 (ja) | 2016-10-05 | 2022-04-08 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗体薬物コンジュゲートの調製方法 |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| BR112019016373B1 (pt) | 2017-02-08 | 2022-01-25 | Medimmune Limited | Conjugado anticorpo-fármaco que se liga ao axl, composição e composição farmacêutica que compreende o mesmo e uso terapêutico do dito conjugado |
| PL3612537T3 (pl) | 2017-04-18 | 2022-11-07 | Medimmune Limited | Koniugaty pirolobenzodiazepin |
| CN110536703B (zh) | 2017-04-20 | 2024-07-12 | Adc治疗有限公司 | 使用抗axl抗体-药物缀合物的组合疗法 |
| JP7145891B2 (ja) | 2017-06-14 | 2022-10-03 | アーデーセー セラピューティクス ソシエテ アノニム | 抗ｃｄ１９ ａｄｃを投与するための投与レジメ |
| KR102270107B1 (ko) | 2017-08-18 | 2021-06-30 | 메디뮨 리미티드 | 피롤로벤조디아제핀 컨쥬게이트 |
| TW201920192A (zh) | 2017-09-20 | 2019-06-01 | 韓商Ｐｈ製藥公司 | 泰蘭他汀（ｔｈａｉｌａｎｓｔａｔｉｎ）類似物 |
| CN108531608B (zh) * | 2018-01-24 | 2020-06-30 | 华南农业大学 | Bmp6基因作为黑山羊产羔数性状的分子标记 |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
| CA3115110A1 (en) | 2018-10-24 | 2020-04-30 | F. Hoffmann-La Roche Ag | Conjugated chemical inducers of degradation and methods of use |
| CN113227119A (zh) | 2018-12-10 | 2021-08-06 | 基因泰克公司 | 用于与含Fc的蛋白质进行位点特异性缀合的光交联肽 |
| GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
| EP3969570A1 (en) * | 2019-05-15 | 2022-03-23 | Novo Nordisk A/S | Methods for obtaining eye field progenitor cells from human pluripotent stem cells |
| GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
| TW202432187A (zh) | 2022-12-23 | 2024-08-16 | 美商建南德克公司 | 小腦蛋白降解劑結合物及其用途 |
| WO2024220546A2 (en) | 2023-04-17 | 2024-10-24 | Peak Bio, Inc. | Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5041538A (en) * | 1987-08-28 | 1991-08-20 | The Salk Institute For Biological Studies | Mammalian follistatin |
| IT1224795B (it) * | 1988-12-01 | 1990-10-24 | Sigma Tau Ind Farmaceuti | Uso dell'acetil d-carnitina nel trattamento terapeutico del glaucoma e composizioni farmaceutiche utili in tale trattamento |
| EP0587751A1 (en) * | 1991-06-05 | 1994-03-23 | The Procter & Gamble Company | Therapeutic compositions for osteoinduction |
| US5364884A (en) * | 1993-01-21 | 1994-11-15 | Baylor College Of Medicine | Arginine compounds as ocular hypotensive agents |
| US5863738A (en) * | 1994-04-29 | 1999-01-26 | Creative Biomolecules, Inc. | Methods of antagonizing OP-1 binding to a cell surface receptor utilizing ALK polypeptides |
| US5606043A (en) | 1994-11-03 | 1997-02-25 | The Regents Of The University Of California | Methods for the diagnosis of glaucoma |
| US5846770A (en) * | 1994-11-22 | 1998-12-08 | Genetics Institute, Inc. | DNA molecules encoding human chordin |
| US5856094A (en) * | 1995-05-12 | 1999-01-05 | The Johns Hopkins University School Of Medicine | Method of detection of neoplastic cells |
| US6040431A (en) * | 1995-06-07 | 2000-03-21 | Stryker Corporation | Single chain analogs of the TGF-β superfamily (morphons) |
| US6248571B1 (en) | 1995-08-31 | 2001-06-19 | Lonza Ag | Method of producing dihydroxypyrimidine derivatives |
| EP0942975A1 (en) * | 1996-11-08 | 1999-09-22 | University Of Iowa Research Foundation | Glaucoma-associated protein and corresponding nucleic acid and their therapeutic and diagnostic uses |
| AU5244998A (en) * | 1996-11-15 | 1998-06-03 | Creative Biomolecules, Inc. | Morphogen-induced regeneration of sense perceptory tissues |
| PT943014E (pt) * | 1996-12-05 | 2007-03-30 | Alcon Mfg Ltd | Métodos para diagnóstico do glaucoma e descoberta de farmacos antiglaucoma |
| US5989885A (en) * | 1997-01-10 | 1999-11-23 | Myriad Genetics, Inc. | Specific mutations of map kinase 4 (MKK4) in human tumor cell lines identify it as a tumor suppressor in various types of cancer |
| WO1998040508A1 (en) * | 1997-03-14 | 1998-09-17 | Selective Genetics, Inc. | Adenoviral vectors with modified tropism |
| US6207450B1 (en) | 1998-04-15 | 2001-03-27 | University Of Iowa Research Foundation | Glaucoma therapeutics and diagnostics based on a novel human transcription factor |
| JP2002537775A (ja) * | 1999-02-26 | 2002-11-12 | ハイバージェン・リミテッド | 糖尿病性腎症を提示する役割を有する遺伝子の同定 |
| WO2000077021A1 (en) * | 1999-06-11 | 2000-12-21 | Human Genome Sciences, Inc. | 48 human secreted proteins |
| JP2003527076A (ja) * | 1999-04-09 | 2003-09-16 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | 骨形態形成タンパク質 |
| AU4700300A (en) * | 1999-05-07 | 2000-11-21 | Human Genome Sciences, Inc. | Serine proteases |
| WO2002077006A1 (en) * | 2001-03-23 | 2002-10-03 | Human Genome Sciences, Inc. | Bone morphogenic protein polynucleotides, polypeptides, and antibodies |
| US20030092019A1 (en) * | 2001-01-09 | 2003-05-15 | Millennium Pharmaceuticals, Inc. | Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia |
| WO2002085909A1 (en) | 2001-04-20 | 2002-10-31 | Vertex Pharmaceuticals Incorporated | 9-deazaguanine derivatives as inhibitors of gsk-3 |
| DE60217152T2 (de) * | 2001-10-31 | 2007-10-31 | Alcon Inc. | Knochen-morphogene proteine (bmp), bmp-rezeptoren und bmp-bindungsproteine und ihre verwendung bei der diagnose und behandlung des glaukoms |
| JP5112061B2 (ja) | 2004-07-02 | 2013-01-09 | ストラスボー | ウエハ処理方法およびシステム |
-
2002
- 2002-10-31 DE DE60217152T patent/DE60217152T2/de not_active Expired - Lifetime
- 2002-10-31 ES ES02802562T patent/ES2278079T3/es not_active Expired - Lifetime
- 2002-10-31 AT AT02802562T patent/ATE349554T1/de not_active IP Right Cessation
- 2002-10-31 US US10/286,152 patent/US7405192B2/en not_active Expired - Fee Related
- 2002-10-31 KR KR1020107026384A patent/KR101072867B1/ko not_active IP Right Cessation
- 2002-10-31 CA CA002463143A patent/CA2463143A1/en not_active Withdrawn
- 2002-10-31 JP JP2003556021A patent/JP4255382B2/ja not_active Expired - Fee Related
- 2002-10-31 PL PL396553A patent/PL214839B1/pl unknown
- 2002-10-31 KR KR1020107001960A patent/KR20100013352A/ko active Application Filing
- 2002-10-31 BR BRPI0213738-0A patent/BR0213738A/pt not_active Application Discontinuation
- 2002-10-31 CN CNA028209176A patent/CN1685055A/zh active Pending
- 2002-10-31 CN CNA2006101467420A patent/CN1966725A/zh active Pending
- 2002-10-31 MX MXPA04003697A patent/MXPA04003697A/es active IP Right Grant
- 2002-10-31 PL PL02373863A patent/PL373863A1/xx not_active Application Discontinuation
- 2002-10-31 WO PCT/US2002/035251 patent/WO2003055443A2/en active Application Filing
- 2002-10-31 KR KR1020117005285A patent/KR20110032003A/ko not_active Application Discontinuation
- 2002-10-31 US US10/492,380 patent/US20050118585A1/en not_active Abandoned
- 2002-10-31 EP EP02802562A patent/EP1440159B1/en not_active Expired - Lifetime
- 2002-10-31 EP EP08019507A patent/EP2053135A1/en not_active Withdrawn
- 2002-10-31 RU RU2004116308/15A patent/RU2336902C2/ru not_active IP Right Cessation
- 2002-10-31 KR KR1020047005671A patent/KR100996226B1/ko not_active IP Right Cessation
-
2004
- 2004-04-05 ZA ZA200402662A patent/ZA200402662B/en unknown
- 2004-12-16 HK HK04110026A patent/HK1069851A1/xx not_active IP Right Cessation
-
2008
- 2008-04-21 US US12/106,653 patent/US7744873B2/en not_active Expired - Fee Related
- 2008-06-03 RU RU2008122296/15A patent/RU2008122296A/ru not_active Application Discontinuation
- 2008-09-08 JP JP2008230352A patent/JP2008301834A/ja active Pending
-
2010
- 2010-04-23 US US12/766,056 patent/US8063013B2/en not_active Expired - Fee Related
-
2011
- 2011-10-26 US US13/281,816 patent/US8389496B2/en not_active Expired - Fee Related
-
2012
- 2012-05-16 RU RU2012120343/15A patent/RU2012120343A/ru not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008122296A (ru) | Морфогенные белки кости (вмр), рецепторы вмр и связывающие вмр белки и их применение для диагностики и лечения глаукомы | |
| Daw et al. | A common region of 10p deleted in DiGeorge and velocardiofacial syndromes | |
| CA2404448C (fr) | Genes impliques dans les maladies inflammatoires de l'intestin et leur utilisation | |
| CN112029900A (zh) | 新型冠状病毒的快速核酸检测方法及检测系统 | |
| KR102313069B1 (ko) | 신규한 황반변성 진단용 마커 및 황반변성 진단방법 | |
| JP2003510349A (ja) | 線条体機能に必要な遺伝子、その使用、およびそれを調節するための化合物 | |
| Nishino et al. | A Novel Mutation in the Mitochondrial tRNAThrGene Associated with a Mitochondrial Encephalomyopathy | |
| Olive et al. | Expression of the mucosal γδ T cell receptor V region repertoire in patients with IgA nephropathy | |
| US6368794B1 (en) | Detection of altered expression of genes regulating cell proliferation | |
| Sahashi et al. | Increased mitochondrial DNA deletions in the skeletal muscle of myotonic dystrophy | |
| US7141658B1 (en) | Single stranded oligonucleotides, probes, primers and method for detecting spirochetes | |
| ES2857513T3 (es) | Oligonucleótidos y su uso | |
| KR101644776B1 (ko) | 참돔 이리도바이러스 검출용 유전자 마커, 및 이를 이용한 원인바이러스의 검출 방법 | |
| RU2788815C1 (ru) | Способ малоинвазивной диагностики глиобластом | |
| WO1997036007A1 (en) | Specific dna probes for the identification of the taenia solium and taenia saginata species | |
| EP3778920B1 (en) | Method for three-dimensional nucleic acid imaging diagnosis of bio-tissue by using isothermal nucleic acid amplification | |
| JPH11113597A (ja) | ヒトミトコンドリアｄｎａを用いた遺伝子診断方法 | |
| KR102180941B1 (ko) | 교모세포종의 진단용 조성물 | |
| DE60311330T2 (de) | Genetisches Verfahren zur Vorhersage des Glaukomarisikos | |
| Pelayo et al. | A method for isolation of rat renal microvessels and mRNA localization | |
| CN101748194A (zh) | 高血压及血管病变疾病风险的遗传学检测芯片及其用途 | |
| Khare et al. | Salivary DNA for sex determination and forensic individualization | |
| WO2000050601A3 (en) | Nucleic acid and amino acid sequences of hemoglobin-response genes in candida albicans and the use of reagents derived from these sequences in the diagnosis of disseminated candida albicans infection | |
| US20030082714A1 (en) | Novel nucleic acid and polypeptide | |
| Iyama et al. | Co-expression of collagen types II and X mRNAs in newly formed hypertrophic chondrocytes of the embryonic chick vertebral body demonstrated by double-fluorescence in situ hybridization |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20121126 |